- Oxford BioDynamics has entered into a development agreement with two of the top 10 global pharmaceutical companies, which are collaborating on an anti PD-L1 therapy.

Oxford BioDynamics would identify biomarkers in whole blood of non-small cell lung carcinoma (NSCLC) patients to assist in differentiating between responders and non-responders to an anti PD-L1 therapy, using its EpiSwitch biomarker platform.

It said the agreement had the potential to be extended in the form of a licensing agreement, which would see the development of an EpiSwitch-class blood-based test, based on the work undertaken as part of the current agreement, for use by the pharmaceutical companies.

Financial terms of the agreement are not disclosed.

Story provided by